Obstructive Sleep ApneaNCT00289666
The Effect of Positive Airway Pressure on Heart Rate Variability
An observational study of Obstructive Sleep Apnea, run by Christiana Care Health Services at 1 site in United States.
Trial summary
This study is designed to determine the effect of continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) on heart rate variability (HRV) in patients with obstructive sleep apnea (OSA). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Obstructive Sleep Apnea
- How many people
- 38 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2003to Sep 2008
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Tertiary Care
Who may be able to join
- Individuals aged 18-75 years old.
- Individuals with diagnosed OSA.
Who cannot join
- 1. Individuals who are receiving treatment for OSA, excluding those being treated by weight loss.
- 2. Individuals who have had pharyngeal surgery (i.e., uvulopalatopharyngoplasty).
- 3. Individuals who have arterial oxygen desaturation episodes or apneic episodes not felt to be due to OSA.
- 4. Individuals whose treatment dosage changes 2 months prior to, or during, the study for antihypertensive and antidiabetic medications and the following medications that may affect the autonomic nervous system: anti-tuberculosis drugs, nitrofurantoin, metronidazole, chloramphenicol, perhexiline maleate, cordarone, clofibrate, tricyclic antidepressants, phenytoin, barbiturates, neuroleptic drugs, antiparkinsonism drugs, and nitrated drugs.
Trial locations and contacts
1 site in 1 country.
United States1 site
Christiana Care Health Service
Newark, Delaware, 19713
About this study
Official title: A Prospective Study to Determine the Effect of Positive Airway Pressure on Heart Rate Variability in Individuals With Obstructive Sleep Apnea
This study is designed to determine the effect of continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) on heart rate variability (HRV) in patients with obstructive sleep apnea (OSA).
Read the detailed description
Visit 1: You will come to the Diabetes and Metabolic Research Center having refrained from taking your routine medications and having not eaten in the last 8 hours, avoided using caffeine-containing beverages and tobacco products in the last 10 hours, and having had no alcoholic beverages in the last 24 hours. In addition, you should refrain from taking any nonprescription drugs and avoid engaging in any vigorous exercise for 48 hours before testing.
For those individuals who have diabetes, a letter or direct verbal permission will be obtained, prior to coming to this study visit, from your eye doctor indicating that you can take part in one of the tests listed below. During this visit, an electrocardiogram (EKG, usual heart rhythm test performed in a doctor's office) will be performed. Your heart rate will also be measured for six minutes with an EKG machine while breathing as deeply as possible. This test, which will be performed twice, will tell whether or not the nerves that go to the heart are normal. You will be asked to blow into a plastic tube for 15 seconds (this is the test for which we will obtain the eye doctor's permission for individuals with diabetes). Your heart rate will be measured during and for 60 seconds after you have finished blowing. This test, which will be performed twice, will tell if the nerves that go to blood vessels are normal. Your blood pressure will be measured four times, one minute apart, while you are lying down. You will then be asked to stand up and your blood pressure will again be measured four more times, each time one minute apart. Change in your heart rate will also be determined as you go from lying down to standing. All individuals will have a fingerstick blood sugar level performed prior to the performance of the tests describe above.
You will have about 2 tablespoons of blood drawn. This blood will be stored (frozen) in case possible risk factors of reduced heart rate variability are discovered in the future. A random urine sample will be stored (frozen) for potential examination for microalbuminuria (protein in the urine) or other possible risk factors. At this visit, we will give you a container with instructions for collecting urine for 24-hours. You will also be given some dietary suggestions (e.g., eating a liberal salt diet) that we would like you to follow for 3-days prior to the 24-hour collection of urine. For individuals with diabetes, a small portion of blood will be checked to determine your blood sugar control level.
Standard medical history questions will be asked during this visit along with questions that assess the likelihood of you falling asleep in various situations. Your medical records from your pulmonary doctor will be reviewed for information about the results of the sleep study you had that determined you have a sleep disorder. You will be asked to keep a diary everyday, for the first six weeks, of how many hours per night you use the treatment for your sleep disorder. This visit will last approximately 1-1 ½ hours.
Visit 2: Within 1-48 hours of completion of the 24-hour urine collection and before you begin treatment for your sleep disorder, you will need to bring the urine specimen to the Diabetes and Metabolic Research Center. A part of this urine will be stored (frozen) for possible testing of a hormone called aldosterone, substances filtered by the kidneys (salt and creatinine), and other potential risk factors. Also at this visit, about 2 tablespoons of blood will be drawn and stored for potential testing of a protein in the blood called renin. You should continue the dietary suggestions (e.g., liberal salt diet) given for the collection of the 24-hour urine until the blood is collected. A part of the blood drawn during this visit will also be stored (frozen) in case potential risk factors of heart rate variability are discovered in the future. This visit will last approximately 15 minutes.
Since some drugs can affect how much your heart speeds up and slows down, if your doctor adds a new drug or changes the dosage of any current drugs you may not be able to continue in this study. Please inform a member of the research staff when your doctor makes any change in your medications.
Before coming to the Diabetes and Metabolic Research Center for visit 3, we will need to determine if you have used your device for the treatment of your sleep disorder enough during the six week period. Therefore, a member of the research staff will call you on a weekly basis to ask you to tell us the information that you have recorded in your diary with regard to how often you used the device for the treatment of your sleep disorder.
Visit 3 (approximately six weeks after you begin treatment for your sleep disorder): If you have used the device that is being used to treat your sleep disorder enough, you will be invited to come for visit 3. All of the tests performed during the first visit will be performed again during visit 3. Thus, you will need to follow the same instructions about food, medicine, and exercise as described under visit 1 before coming to visit 3. You will again have a fingerstick blood sugar level performed. In addition, about 2 tablespoons of blood will be drawn. This blood and a random urine sample will be stored (frozen) in case possible risk factors of reduced heart rate variability are discovered in the future and in case these factors need to be examined before and after treatment for a sleep disorder. The same questions asked with regard to the likelihood of you falling asleep in various situations will be asked. This visit will last approximately 1-1 ½ hours.
Visit 4 (approximately 18-months after you begin treatment for your sleep disorder): If you continue to use the device that is being used to treat your sleep disorder for 18-months, you will be invited to come for visit 4. All of the tests performed during the first visit will be performed again during visit 4. Thus, you will need to follow the same instructions about food, medicine, and exercise as described under visit 1 before coming to visit 4. You will again have a fingerstick blood sugar level performed. In addition, about 2 tablespoons of blood will be drawn. This blood and a random urine sample will be stored (frozen) in case possible risk factors of reduced heart rate variability are discovered in the future and in case these factors need to be examined before and after treatment for a sleep disorder. For individuals with diabetes, a small portion of blood will be checked to determine your blood sugar control level. The same questions asked with regard to the likelihood of you falling asleep in various situations will be asked again. This visit will last approximately 1-1 ½ hours.
- Conditions
- Obstructive Sleep Apnea
- Keywords
- Sleep Disorder, CPAP
- Medical subject headings
- Sleep Apnea, Obstructive, Sleep Wake Disorders
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2006 (estimated)
- Study startJul 2003
- Primary completionMar 2007
- Study completionSep 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Christiana Care Health Services
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Raelene Maser, Christiana Care Health Services
- Investigators
- Raelene E Maser, PhD, Principal investigator, University of Delaware
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00289666
- Sponsor's protocol ID
- 23011
- Status last verified
- Sep 2008
- First submitted
- 9 Feb 2006
- Last updated
- 11 Jul 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
Maser RE, Lenhard MJ, Rizzo AA, Vasile AA. Continuous positive airway pressure therapy improves cardiovascular autonomic function for persons with sleep-disordered breathing. Chest. 2008 Jan;133(1):86-91. doi: 10.1378/chest.07-1580. Epub 2007 Oct 20.
PubMed 17951618
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study to Determine the Effect of Positive Airway Pressure on Heart Rate Variability in Individuals With Obstructive Sleep Apnea
- ClinicalTrials.gov ID
- NCT00289666
- Acronym / sponsor ID
- 23011
- Conditions
- Obstructive Sleep Apnea
- Keywords
- Sleep Disorder, CPAP
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- Christiana Care Health ServicesUniversity, hospital or other
- Study start
- Jul 2003
- Primary completion
- Mar 2007 (actual)
- Study completion
- Sep 2008 (actual)
- First posted
- 10 Feb 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to determine the effect of continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) on heart rate variability (HRV) in patients with obstructive sleep apnea (OSA).
Detailed description
Visit 1: You will come to the Diabetes and Metabolic Research Center having refrained from taking your routine medications and having not eaten in the last 8 hours, avoided using caffeine-containing beverages and tobacco products in the last 10 hours, and having had no alcoholic beverages in the last 24 hours. In addition, you should refrain from taking any nonprescription drugs and avoid engaging in any vigorous exercise for 48 hours before testing.
For those individuals who have diabetes, a letter or direct verbal permission will be obtained, prior to coming to this study visit, from your eye doctor indicating that you can take part in one of the tests listed below. During this visit, an electrocardiogram (EKG, usual heart rhythm test performed in a doctor's office) will be performed. Your heart rate will also be measured for six minutes with an EKG machine while breathing as deeply as possible. This test, which will be performed twice, will tell whether or not the nerves that go to the heart are normal. You will be asked to blow into a plastic tube for 15 seconds (this is the test for which we will obtain the eye doctor's permission for individuals with diabetes). Your heart rate will be measured during and for 60 seconds after you have finished blowing. This test, which will be performed twice, will tell if the nerves that go to blood vessels are normal. Your blood pressure will be measured four times, one minute apart, while you are lying down. You will then be asked to stand up and your blood pressure will again be measured four more times, each time one minute apart. Change in your heart rate will also be determined as you go from lying down to standing. All individuals will have a fingerstick blood sugar level performed prior to the performance of the tests describe above.
You will have about 2 tablespoons of blood drawn. This blood will be stored (frozen) in case possible risk factors of reduced heart rate variability are discovered in the future. A random urine sample will be stored (frozen) for potential examination for microalbuminuria (protein in the urine) or other possible risk factors. At this visit, we will give you a container with instructions for collecting urine for 24-hours. You will also be given some dietary suggestions (e.g., eating a liberal salt diet) that we would like you to follow for 3-days prior to the 24-hour collection of urine. For individuals with diabetes, a small portion of blood will be checked to determine your blood sugar control level.
Standard medical history questions will be asked during this visit along with questions that assess the likelihood of you falling asleep in various situations. Your medical records from your pulmonary doctor will be reviewed for information about the results of the sleep study you had that determined you have a sleep disorder. You will be asked to keep a diary everyday, for the first six weeks, of how many hours per night you use the treatment for your sleep disorder. This visit will last approximately 1-1 ½ hours.
Visit 2: Within 1-48 hours of completion of the 24-hour urine collection and before you begin treatment for your sleep disorder, you will need to bring the urine specimen to the Diabetes and Metabolic Research Center. A part of this urine will be stored (frozen) for possible testing of a hormone called aldosterone, substances filtered by the kidneys (salt and creatinine), and other potential risk factors. Also at this visit, about 2 tablespoons of blood will be drawn and stored for potential testing of a protein in the blood called renin. You should continue the dietary suggestions (e.g., liberal salt diet) given for the collection of the 24-hour urine until the blood is collected. A part of the blood drawn during this visit will also be stored (frozen) in case potential risk factors of heart rate variability are discovered in the future. This visit will last approximately 15 minutes.
Since some drugs can affect how much your heart speeds up and slows down, if your doctor adds a new drug or changes the dosage of any current drugs you may not be able to continue in this study. Please inform a member of the research staff when your doctor makes any change in your medications.
Before coming to the Diabetes and Metabolic Research Center for visit 3, we will need to determine if you have used your device for the treatment of your sleep disorder enough during the six week period. Therefore, a member of the research staff will call you on a weekly basis to ask you to tell us the information that you have recorded in your diary with regard to how often you used the device for the treatment of your sleep disorder.
Visit 3 (approximately six weeks after you begin treatment for your sleep disorder): If you have used the device that is being used to treat your sleep disorder enough, you will be invited to come for visit 3. All of the tests performed during the first visit will be performed again during visit 3. Thus, you will need to follow the same instructions about food, medicine, and exercise as described under visit 1 before coming to visit 3. You will again have a fingerstick blood sugar level performed. In addition, about 2 tablespoons of blood will be drawn. This blood and a random urine sample will be stored (frozen) in case possible risk factors of reduced heart rate variability are discovered in the future and in case these factors need to be examined before and after treatment for a sleep disorder. The same questions asked with regard to the likelihood of you falling asleep in various situations will be asked. This visit will last approximately 1-1 ½ hours.
Visit 4 (approximately 18-months after you begin treatment for your sleep disorder): If you continue to use the device that is being used to treat your sleep disorder for 18-months, you will be invited to come for visit 4. All of the tests performed during the first visit will be performed again during visit 4. Thus, you will need to follow the same instructions about food, medicine, and exercise as described under visit 1 before coming to visit 4. You will again have a fingerstick blood sugar level performed. In addition, about 2 tablespoons of blood will be drawn. This blood and a random urine sample will be stored (frozen) in case possible risk factors of reduced heart rate variability are discovered in the future and in case these factors need to be examined before and after treatment for a sleep disorder. For individuals with diabetes, a small portion of blood will be checked to determine your blood sugar control level. The same questions asked with regard to the likelihood of you falling asleep in various situations will be asked again. This visit will last approximately 1-1 ½ hours.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Tertiary Care
Key inclusion criteria (2 listed)
- Individuals aged 18-75 years old.
- Individuals with diagnosed OSA.
Key exclusion criteria (4 listed)
- 1. Individuals who are receiving treatment for OSA, excluding those being treated by weight loss.
- 2. Individuals who have had pharyngeal surgery (i.e., uvulopalatopharyngoplasty).
- 3. Individuals who have arterial oxygen desaturation episodes or apneic episodes not felt to be due to OSA.
- 4. Individuals whose treatment dosage changes 2 months prior to, or during, the study for antihypertensive and antidiabetic medications and the following medications that may affect the autonomic nervous system: anti-tuberculosis drugs, nitrofurantoin, metronidazole, chloramphenicol, perhexiline maleate, cordarone, clofibrate, tricyclic antidepressants, phenytoin, barbiturates, neuroleptic drugs, antiparkinsonism drugs, and nitrated drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2016.
- Results publication: PubMed 17951618Maser RE, Lenhard MJ, Rizzo AA, Vasile AA. Continuous positive airway pressure therapy improves cardiovascular autonomic function for persons with sleep-disordered breathing. Chest. 2008 Jan;133(1):86-91. doi: 10.1378/chest.07-1580. Epub 2007 Oct 20.
Related trials for Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingObservational study
Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea
Pediatric Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raelene E Maser, PhD principal investigator
University of Delaware
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obstructive Sleep Apnea, run by Christiana Care Health Services at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00289666, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2016; AzTrials last refreshed its copy on 7 Nov 2026.